PSIL ADVISORSHARES PSYCHEDELICS ETF
- 1.190
- -0.010-0.83%
Russell 3000: Inovio, Ocugen Among Healthcare Additions; Assertio, Ginkgo Bioworks Among Deletions
Mind Medicine a New Outperform at Baird on LSD-based Asset for Anxiety
Alkermes to Present Promising Narcolepsy Treatment Data at Annual Sleep Conference
Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024PRNewswire– Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibran
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
HC Wainwright & Co. Reiterates Buy on Mind Medicine, Maintains $35 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Mind Medicine (NASDAQ:MNMD) with a Buy and maintains $35 price target.
'Top Federal Drug Official Says There's 'Tremendous Excitement' Around Psychedelic Medicine, But 'It's Not Magic'' - Marijuana Moment
'Top Federal Drug Official Says There's 'Tremendous Excitement' Around Psychedelic Medicine, But 'It's Not Magic'' - Marijuana Moment
6 Analysts Assess Alkermes: What You Need To Know
Alkermes (NASDAQ:ALKS) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table encapsulates their recent ratings
Alkermes Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/23/2024 98.27% Cantor Fitzgerald $43 → $48 Maintains Overweight 05/02/2024 44.57% HC Wainwright & Co. →
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B
HC Wainwright & Co. Reiterates Buy on ATAI Life Sciences, Maintains $15 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates ATAI Life Sciences (NASDAQ:ATAI) with a Buy and maintains $15 price target.
ATAI Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/17/2024 742.7% HC Wainwright & Co. → $15 Reiterates Buy → Buy 04/04/2024 — Cantor Fitzgerald Reiterate
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersLucy Scientific Discovery (NASDAQ:LSDI) shares moved upwards by 205.8% to $1.56 during Thursday's regular session. The company's market cap stands at $2.7 million. SINTX Techs (NASDAQ:SINT) sha
Jim Cramer: This Industrial Company Is 'Absolutely Terrific', Recommends Buying Modine Manufacturing
On CNBC's "Mad Money Lightning Round," Jim Cramer believes in Moderna, Inc. (NASDAQ:MRNA).On May 14, Evercore ISI Group analyst Cory Kasimov initiated coverage on Moderna with an In-Line rating and an
ATAI Life Sciences Q1 EPS $(0.17) Beats $(0.18) Estimate, Cash $18.87M
ATAI Life Sciences (NASDAQ:ATAI) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.18) by 5.56 percent. This is a 19.05 percent increase over losses of $(
NRX Pharmaceuticals Q1 EPS $(0.74) Misses $(0.37) Estimate
NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly losses of $(0.74) per share which missed the analyst consensus estimate of $(0.37) by 100 percent. This is a 53.75 percent increase over losses of
Oppenheimer Reiterates Outperform on Mind Medicine, Lowers Price Target to $20
Oppenheimer analyst Francois Brisebois reiterates Mind Medicine (NASDAQ:MNMD) with a Outperform and lowers the price target from $29 to $20.
Seritage Growth Properties Posts Q1 Loss, Joins Fortrea Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.Shares of Seritage Growth Properties (NYSE:SRG) fell sharply in today's pre-market trading after
Compass Pathways Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 1357.99% HC Wainwright & Co. → $120 Reiterates Buy → Buy 04/30/2024 — Cantor Fitzgerald Reiter
HC Wainwright & Co. Maintains Buy on Mind Medicine, Lowers Price Target to $35
HC Wainwright & Co. analyst Patrick Trucchio maintains Mind Medicine (NASDAQ:MNMD) with a Buy and lowers the price target from $75 to $35.
Mind Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 280.43% HC Wainwright & Co. $75 → $35 Maintains Buy 04/15/2024 117.39% Leerink Partners → $20 I